Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report released on Saturday. The firm set a “sell” rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.33 on Friday. The company has a market cap of $4.03 million, a PE ratio of -0.05 and a beta of 0.43. Oragenics has a 12 month low of $0.25 and a 12 month high of $7.74. The company has a fifty day moving average price of $0.33 and a two-hundred day moving average price of $0.81.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.